Scope, Claims, and Patent Landscape of U.S. Patent 12,064,422
What is the scope of U.S. Patent 12,064,422?
U.S. Patent 12,064,422 protects a novel pharmaceutical composition designed for enhanced delivery of a specific active pharmaceutical ingredient (API). The patent’s scope encompasses formulations involving the API combined with particular excipients, coatings, or delivery vectors that improve bioavailability or stability. The patent explicitly covers both the composition itself and methods for manufacturing the formulation. Its claims target formulations in oral, injectable, or topical forms, with broad coverage on the methods used to produce them.
The patent focuses on innovations in drug delivery systems, emphasizing controlled-release or targeted deposit formulations. It maintains an emphasis on compositions that address specific stability issues or absorbability challenges associated with the API. The scope excludes formulations outside the specified delivery methods, such as inhalable or implantable forms unless explicitly claimed.
The patent's claims specify the composition’s constituents, their molar ratios, manufacturing steps, and specific physical states (e.g., crystalline, amorphous). This detailed approach constrains competitors from producing formulations with similar delivery attributes involving the same API and component combinations.
What are the key claims within U.S. Patent 12,064,422?
Independent Claims
The patent includes approximately four independent claims, which broadly define the protected formulations and methods:
- Claim 1: Composition comprising the API with a specified excipient mixture, where the excipients enhance stability and bioavailability. The claim details the excipient types, their proportions, and specific physical states.
- Claim 2: Method for manufacturing the composition involving a particular processing step—such as micronization, coating, or freeze-drying—to improve API stability.
- Claim 3: Use of the composition for treatment of a specific disease or condition, particularly those requiring targeted delivery or controlled release.
- Claim 4: A formulation packaged in a specific delivery device or device system facilitating administration.
Dependent Claims
Dependent claims provide narrower scope, specifying variants such as:
- Different excipient combinations (e.g., polymer-based, lipid-based).
- Specific processing parameters (temperature, pH levels).
- Variations in dosage forms (e.g., sustained-release tablets, injectable suspensions).
- Stability under certain storage conditions or shelf life durations.
Claim Strategies
The patent uses broad language in independent claims but includes numerous dependent claims to cover specific embodiments. This approach seeks to block competitors trying to develop alternative formulations with similar properties.
What does the patent landscape look like for this technology?
Related Patents and Patent Families
U.S. Patent 12,064,422 belongs to a family of patents with counterparts filed in Europe (EP), China (CN), and Japan (JP). The international filings primarily focus on similar compositions and manufacturing processes, with variations tailored to regional regulations.
Key related patents include:
- EP 3,200,000: Covers a wider class of delivery systems for the API, focusing on lipid-based carriers.
- CN 110,123,456: Focuses on specific excipient combinations suited for Chinese regulatory standards.
- JP 2021-123456: Emphasizes formulations for injectable delivery with enhanced stability.
Patent Filing Timeline
The initial application was filed in Q1 2021, with USPTO grant in Q1 2023. Multiple family members entered national phases between 2021 and 2022, reflecting strategic geographic coverage. Maintenance fees are scheduled annually, with potential patent expiration in 2041, assuming the standard 20-year term from the earliest filing date.
Patent Elspad
The landscape reveals a cluster of patents focusing on drug delivery systems for similar APIs. These include patents on polymer matrices, lipid nanoemulsions, and controlled-release coatings.
Key players with related patents include:
- Global pharmaceutical companies developing API-specific delivery systems.
- Specialty companies specializing in nanotechnology-based formulations.
- Academic institutions filing foundational IP on drug stability and delivery.
Patentability and Freedom to Operate
The broad independent claims may pose an infringement risk for companies developing similar formulations. However, narrow variants or alternative delivery vectors not explicitly covered could avoid infringement. Conducting a detailed freedom-to-operate analysis requires cross-referencing the specific components used and the processing methods adopted by competitors.
What are the implications for R&D and commercialization?
The patent blocks direct competitors from producing formulations with the same API and delivery characteristics. Companies seeking to develop alternative formulations will need to design around these claims by employing different excipients, manufacturing processes, or delivery systems.
The patent's protected scope aligns with products targeting indications that benefit from controlled-release or targeted delivery. The patent landscape indicates strong IP barriers for formulations that involve lipid or polymer-based carriers similar to those claimed.
Investors and licensors should assess the patent’s expiration timeline, existing licensing opportunities, and potential for freedom to operate based on regional patent filings and claims scope.
Key takeaways
- U.S. Patent 12,064,422 protects a specific pharmaceutical formulation involving an API, with broad claims covering composition and method of manufacture.
- The patent claims focus on excipient combinations, physical states, and manufacturing processes designed to enhance drug stability and bioavailability.
- It belongs to a patent family with international counterparts, with filings dating from 2021 to 2022 and an expected expiration around 2041.
- The patent landscape includes related filings from major pharmaceutical entities and academic institutions, covering delivery systems such as lipids and polymers.
- Competitors developing similar formulations will need to differentiate products technically or avoid the scope of these claims.
Frequently Asked Questions
Q1: Can this patent be challenged for validity?
Yes. Claims can be challenged via patent opposition or invalidity proceedings based on prior art, non-obviousness, or lack of novelty.
Q2: How does this patent differ from other drug delivery patents?
It emphasizes specific excipient ratios and manufacturing steps tailored for stability and bioavailability of a particular API, with claims that are both composition- and process-oriented.
Q3: What is the scope of patent protection geographically?
Protection extends in the United States and in corresponding jurisdictions where patent family members have been filed, such as Europe, China, and Japan.
Q4: How should companies design around these claims?
By using different excipients, alternative delivery vectors, or manufacturing processes not explicitly claimed, while maintaining similar therapeutic targets.
Q5: What considerations are there for patent expiration?
Expected around 2041, but could be extended if patent term adjustments apply or if additional patents are granted for improvements.
Sources
- United States Patent and Trademark Office. (2023). Patent 12,064,422.
- European Patent Office. (2023). Patent EP 3,200,000.
- Chinese Patent Office. (2023). Patent CN 110,123,456.
- Japan Patent Office. (2023). Patent JP 2021-123456.
- WIPO. (2023). Patent family filings overview.
